Nanoparticle-based therapeutic strategies for mitochondrial dysfunction in cardiovascular disease

Area of Science:

• Biomedical Engineering
• Cardiovascular Medicine
• Mitochondrial Biology

Background:

• Cardiovascular diseases (CVD) represent a significant global health burden and leading cause of mortality.
• Current therapeutic strategies for CVD often lack the ability to address underlying pathological processes.
• Mitochondrial dysfunction is increasingly recognized as a critical contributor to CVD pathophysiology.

Purpose of the Study:

• To review the role of mitochondrial dysfunction in CVD progression.
• To explore the application of nanoparticle-based delivery systems for mitochondrial targeting in CVD.
• To summarize advancements, advantages, and challenges in this therapeutic approach.

Main Methods:

• Literature review focusing on mitochondrial dysfunction in CVD.
• Analysis of nanoparticle-based delivery systems for mitochondrial targeting.
• Categorization of nanosystems including peptide-based, polymeric, liposomes, and lipid nanoparticles.

Main Results:

• Mitochondrial dysfunction is implicated in the pathogenesis of various cardiovascular diseases.
• Nanoparticle systems show potential for targeted delivery of therapeutics to mitochondria.
• Various nanocarriers, including peptide-based, polymeric, liposomes, and lipid nanoparticles, have been investigated.

Conclusions:

• Targeting mitochondria via nanoparticle delivery presents a promising therapeutic strategy for CVD.
• Further research is needed to overcome challenges in nanocarrier design and clinical translation for CVD treatment.
• Optimizing nanoparticle-based mitochondrial targeting could lead to more effective CVD therapies.